National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Lung Cancer Screening (PDQ®)
Patient VersionHealth Professional VersionLast Modified: 04/03/2008



Purpose of This PDQ Summary







Summary of Evidence






Significance






Evidence of Benefit






Get More Information From NCI






Changes To This Summary (04/03/2008)






Questions or Comments About This Summary






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

President's Cancer Panel Annual Report: 2006-2007

Cancer Trends Progress Report: 2007 Update

Past Highlights
HPV Vaccines for Cervical Cancer
Summary of Evidence

Screening for Lung Cancer with Chest X-Ray and/or Sputum Cytology
        Benefits
        Harms
Screening for Lung Cancer with Low-Dose Helical Computed Tomography (LDCT)
        Benefits
        Harms

Separate PDQ summaries on Lung Cancer Prevention, Small Cell Lung Cancer Treatment, Non-Small Cell Lung Cancer Treatment, and Levels of Evidence for Cancer Screening and Prevention Studies are also available.

Screening for Lung Cancer with Chest X-Ray and/or Sputum Cytology

Benefits

Based on fair evidence, screening does not reduce mortality from lung cancer.

Description of the Evidence

  • Study Design: Evidence obtained from randomized controlled trials.
  • Internal Validity: Fair, due to lack of unscreened groups and contamination.
  • Consistency: Good.
  • Direction and Magnitude of Effect: No evidence of effect.
  • External Validity: Fair, due to lack of women and minority groups.
Harms

Based on solid evidence, screening would lead to false-positive tests and unnecessary invasive diagnostic procedures and treatments.

Description of the Evidence

  • Study Design: Evidence obtained from randomized controlled trials.
  • Internal Validity: Fair.
  • Consistency: Good.
  • Direction and Magnitude of Effect: False-positive results range from 4% to 15%; there is a possibility of overdiagnosis and overtreatment (magnitude uncertain).
  • External Validity: Fair.
Screening for Lung Cancer with Low-Dose Helical Computed Tomography (LDCT)

Benefits

The evidence is inadequate to determine whether screening reduces mortality from lung cancer.

Description of the Evidence

  • Study Design: Evidence obtained from cohort or case-control studies.
  • Internal Validity: Poor for answering the question of mortality reduction from screening with LDCT.
  • Consistency: Good.
  • Direction and Magnitude of Effect: Cannot determine from the available studies.
  • External Validity: Not applicable, as the internal validity of the evidence is poor.
Harms

Based on solid evidence, screening would lead to false-positive tests and unnecessary invasive diagnostic procedures and treatments.

Description of the Evidence

  • Study Design: Evidence obtained from cohort or case-control studies.
  • Internal Validity: Poor.
  • Consistency: Good.
  • Direction and Magnitude of Effect: False-positive results range from 20% to 50%; overdiagnosis and overtreatment are possible (magnitude uncertain).
  • External Validity: Fair.

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov